Skip to main content
S&P 5007,585.73-0.45%DOW52,093.11-0.63%NASDAQ25,981.57-0.78%BTC$75,959.00-1.46%ETH$2,407.52-3.10%GOLD$4,384.60+1.20%OIL$103.95-1.78%
Smart Investors Daily
PH

NYSE · PHG

Koninklijke Philips N.V.

Healthcare · Medical - Devices

$24.90

Down-$0.18 (-0.72%)

Updated Sep 16, 2026, 9:22 AM

SID Score

4.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
25.7B
P/E ratio
134.3
Dividend yield
3.88%
52-week range
$23.85 – $33.44
Volume
814.95K
Avg. volume
750.85K

Price performance

PHG price history

1M range · 20 trading sessions · Daily adjusted prices

PHG closed at $24.90 after 20 trading sessions, down 8.12% for the selected period.

Last close
$24.90
Period change
-8.12%
Period low
$24.59
Period high
$27.62
Daily close
View OHLC price history
PHG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$24.88$24.9392$24.73$24.90814.95K
Sep 14, 2026$25.05$25.18$24.8999$25.08867.56K
Sep 11, 2026$24.79$24.825$24.485$24.59765.41K
Sep 10, 2026$24.79$24.835$24.57$24.60817.24K
Sep 9, 2026$25.15$25.235$25.01$25.02874.2K
Sep 8, 2026$25.69$25.69$25.275$25.29677.22K
Sep 4, 2026$25.91$26.02$25.86$25.89455.48K
Sep 3, 2026$26.34$26.34$25.54$26.05951.9K
Sep 2, 2026$26.42$26.83$26.37$26.37792.8K
Sep 1, 2026$26.96$26.97$26.50$26.59732.6K
Aug 31, 2026$26.72$26.76$26.54$26.57631.43K
Aug 28, 2026$26.90$26.94$26.66$26.72531.71K
Aug 27, 2026$26.72$27.08$26.61$26.92548.56K
Aug 26, 2026$27.32$27.32$26.86$26.99751.85K
Aug 25, 2026$27.33$27.455$27.23$27.43469.02K
Aug 24, 2026$27.52$27.69$27.44$27.52566.57K
Aug 21, 2026$27.31$27.62$27.16$27.42753.89K
Aug 20, 2026$27.53$27.765$27.50$27.50586.71K
Aug 19, 2026$27.25$27.655$27.23$27.62827.45K
Aug 18, 2026$27.10$27.355$27.045$27.10702.68K

Latest PHG news

The latest Smart Investors Daily articles mentioning PHG.

Stock researchCompany · Overview

PHG research

Overview

Company profile and research snapshot.

Company profile

Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
PHG recent ratings
DateFirmRatingTarget
Jul 12, 2026DAY BY DAYBuy—
Jul 8, 2026ROTHSCHILD & CO REDBURNNeutral—
Jul 6, 2026JEFFERIESHold—
Jun 7, 2026BAADER EUROPE / ALPHAVALUEBuy—
Jun 1, 2026ING FMHold—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Philips Launches Revolutionary Lumea® IPL 9900 Pro: the First At-Home Intense Pulsed Light (IPL) Hair Removal Device With Real-Time Audio Guidance That Talks to You During Treatment

CAMBRIDGE, Mass., September 08, 2026--Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, this month launched the Philips Lumea IPL 9900 Pro, transforming at-home hair removal into a personalized and rewarding self-care routine. Philips Lumea IPL 9900 Pro is the first at-home IPL with audio feedback and motion guidance that talks to users2, helping give them greater confidence in effective treatment. As the world’s no. 1 IPL brand3, Philips brings 25 years of IPL research

Yahoo · Sep 3, 2026

Philips advances women’s health ultrasound with new single-transducer solution

Philips eV14-2v transducer Philips eV14-2v transvaginal transducer, designed to support a broad range of gynecology and early obstetrics exams. Clinician holding Philips eV14-2v transducer A clinician holds the Philips eV14-2v transvaginal transducer. Patient consultation with Philips Alturion ultrasound A clinician consults with a patient alongside the Philips Alturion ultrasound system and eV14-2v transducer during a women’s health appointment. September 3, 2026 FDA 510(k) cleared and CE marke

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By